Main Products/ Services/ Pipelines & Platforms
Leading Pipeline Assets: APP13007 • Clobetasol Propionate Ophthalmic Nanosuspension for Inflammation and Pain after Cataract Surgery • Less-frequent administration: BID x 2 weeks; increased patient compliance • Convincing efficacy: Rapid clearance of inflammation and progression to pain-free • Enhanced formulation: superior homogeneity for more comfortable administration • Compelling safety profile: no ocular toxicity; low incidence of IOP elevation TSY-0110 • ADC biosimilar of Kadcyla (T-DM1) • TSY-0110 is in late-preclinical development stages, planning for CTA filing • Seeking interested parties for regional/global licensing or co-development Proprietary Platform: APNT Nanoparticle Formulation Platform • Operates on the principle of particle size reduction to improve dissolution and bioavailability, with lower risk of contamination • Free of solvents and harsh additives • Stable formulation/ Increased Bioavailability/ Enhanced Safety Profile/ Increased IP value of asset • Optimized for oral, inhaler, topical, and ophthalmic administration routes
Business Interests
Seeking out-licensing opportunities for leading pipeline assets. Seeking co-development partner for Proprietary Platform.
Contact Info
Wayne Wei
Director, Business Development
+886-2-2755-7659
waynewei@formosapharma.com